Cardiol Therapeutics (TSE:CRDL) Hits New 52-Week Low – Should You Sell?

Cardiol Therapeutics Inc. (TSE:CRDL – Get Free Report) shares hit a new 52-week low on Friday. The stock traded as low as C$1.22 and last traded at C$1.23, with a volume of 68,664 shares. The stock had previously closed at C$1.25.

Cardiol Therapeutics Stock Down 2.4%

The stock has a 50 day moving average of C$1.88 and a 200-day moving average of C$1.82. The firm has a market capitalization of C$155.78 million, a P/E ratio of -3.59 and a beta of 0.14. The company has a debt-to-equity ratio of 0.35, a quick ratio of 6.84 and a current ratio of 6.26.

Cardiol Therapeutics (TSE:CRDL – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported C($0.11) earnings per share for the quarter. Research analysts predict that Cardiol Therapeutics Inc. will post -0.49 earnings per share for the current fiscal year.

Cardiol Therapeutics Company Profile

(Get Free Report)

Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.

Further Reading

Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.